Related references
Note: Only part of the references are listed.Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling
Rune Busk Damgaard et al.
EMBO MOLECULAR MEDICINE (2013)
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Madhusudhanan Sukumar et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch
Patrick M. Gubser et al.
NATURE IMMUNOLOGY (2013)
The PI3K/Akt/mTOR Pathway Is Implicated in the Premature Senescence of Primary Human Endothelial Cells Exposed to Chronic Radiation
Ramesh Yentrapalli et al.
PLOS ONE (2013)
Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K
Mary Ellen Conley et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells
David K. Finlay et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Signal Integration by Akt Regulates CD8 T Cell Effector and Memory Differentiation
Eui Ho Kim et al.
JOURNAL OF IMMUNOLOGY (2012)
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy
M. V. Astle et al.
ONCOGENE (2012)
mTOR, linking metabolism and immunity
Xiaojin Xu et al.
SEMINARS IN IMMUNOLOGY (2012)
mTOR and metabolic pathways in T cell quiescence and functional activation
Kai Yang et al.
SEMINARS IN IMMUNOLOGY (2012)
PI3K-PKB/Akt Pathway
Brian A. Hemmings et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
Transcriptional control of effector and memory CD8+ T cell differentiation
Susan M. Kaech et al.
NATURE REVIEWS IMMUNOLOGY (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Activation of mTORC2 by Association with the Ribosome
Vittoria Zinzalla et al.
CELL (2011)
Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega
Fabian Sievers et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
Second messenger role for Mg2+ revealed by human T-cell immunodeficiency
Feng-Yen Li et al.
NATURE (2011)
Molecular Pathogenesis of EBV Susceptibility in XLP as Revealed by Analysis of Female Carriers with Heterozygous Expression of SAP
Umaimainthan Palendira et al.
PLOS BIOLOGY (2011)
B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans
Danielle T. Avery et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
Alex Berndt et al.
NATURE CHEMICAL BIOLOGY (2010)
PI3 Kinase Signals BCR-Dependent Mature B Cell Survival
Lakshmi Srinivasan et al.
CELL (2009)
mTOR regulates memory CD8 T-cell differentiation
Koichi Araki et al.
NATURE (2009)
Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110 alpha and are disrupted in oncogenic p85 mutants
Haiyan Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane
Diana Mandelker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking
Linda V. Sinclair et al.
NATURE IMMUNOLOGY (2008)
Class IPI3K in oncogenic cellular transformation
L. Zhao et al.
ONCOGENE (2008)
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
Li Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Oncogenic signaling of class IPI3K isoforms
A. Denley et al.
ONCOGENE (2008)
Structural comparisons of class I phosphoinositide 3-kinases
L. Mario Amzel et al.
NATURE REVIEWS CANCER (2008)
The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations
Chuan-Hsiang Huang et al.
SCIENCE (2007)
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation
Philippe P. Roux et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16
C. Billottet et al.
ONCOGENE (2006)
Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling
Sidne A. Omori et al.
IMMUNITY (2006)
Identification of variations in the human phosphoinositide 3-kinase p110δ gene in children with primary B-cell immunodeficiency of unknown aetiology
S. -T. Jou et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2006)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Oncogenic PI3K deregulates transcription and translation
AG Bader et al.
NATURE REVIEWS CANCER (2005)
Fuel feeds function: Energy metabolism and the T-cell response
CJ Fox et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Generation and maintenance of immunological memory
TS Gourley et al.
SEMINARS IN IMMUNOLOGY (2004)
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells
JM Brenchley et al.
BLOOD (2003)
PI3K in lymphocyte development, differentiation and activation
K Okkenhaug et al.
NATURE REVIEWS IMMUNOLOGY (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
T cell-specific loss of Pten leads to defects in central and peripheral tolerance
A Suzuki et al.
IMMUNITY (2001)
Share Paper
